2019
DOI: 10.1111/head.13533
|View full text |Cite
|
Sign up to set email alerts
|

We Still Do Not Know Whether Topical Ambroxol Is Effective in Classical Trigeminal Neuralgia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 6 publications
0
2
0
Order By: Relevance
“…Lastly, Kern et al report a small series of trigeminal neuralgia patients who responded to topical ambroxol 20%, an expectorant with local anesthetic properties considered approximately 40 times stronger than lidocaine 12 . Importantly, the ambroxol series was open‐label, and the authors did not specify the total number of trigeminal neuralgia patients treated, making it difficult to assess their overall responder rate 13 . Limitations aside, these papers demonstrate ongoing efforts to expand the arsenal of treatments for this very painful disorder.…”
Section: Additional Nosological Complexitiesmentioning
confidence: 99%
See 1 more Smart Citation
“…Lastly, Kern et al report a small series of trigeminal neuralgia patients who responded to topical ambroxol 20%, an expectorant with local anesthetic properties considered approximately 40 times stronger than lidocaine 12 . Importantly, the ambroxol series was open‐label, and the authors did not specify the total number of trigeminal neuralgia patients treated, making it difficult to assess their overall responder rate 13 . Limitations aside, these papers demonstrate ongoing efforts to expand the arsenal of treatments for this very painful disorder.…”
Section: Additional Nosological Complexitiesmentioning
confidence: 99%
“…This virtual issue begins with an excellent and detailed over- 12 Importantly, the ambroxol series was open-label, and the authors did not specify the total number of trigeminal neuralgia patients treated, making it difficult to assess their overall responder rate. 13 Limitations aside, these papers demonstrate ongoing efforts to expand the arsenal of treatments for this very painful disorder.…”
mentioning
confidence: 99%